The emerging role of anti‐CD25 directed therapies as both immune modulators and targeted agents in cancer. (30th May 2017)

• Record Type: Journal Article
• Authors: Flynn, Michael J.; Hartley, John A.
• Is Part Of: British journal of haematology. Volume 179:Number 1(2017)
• Page Start: 20
• Page End: 35
• Publication Date: 2017-05-30
• Subjects: CD25 -- interleukin‐2 receptor -- regulatory T cells -- CD25‐expressing malignancies -- anti‐CD25 targeted therapy; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; 616.15
• DOI: 10.1111/bjh.14770
• Languages: English
• ISSNs: 0007-1048

Abstract

Summary: CD25 (also termed IL2RA) forms one component of the high‐affinity heterotrimeric interleukin 2 (IL2) receptor on activated T cells. Its affinity for IL2 and cellular function are tightly regulated and vary in different cell types. The high frequency of CD25 on the surface of many different haematological tumour cells is now well established and, apart from its prognostic significance, CD25 may be present on leukaemic stem cells and enable oncogenic signalling pathways in leukaemic cells. Additionally, high CD25 expression in activated circulating immune cells and Tregs is a factor that has already been exploited by IL2 immunotherapies for treatment of tumours and autoimmune disease. The relative clinical safety and efficacy of administering anti‐CD25 radioimmunoconjugates and immunotoxins in various haematological tumour indications has been established and clinical trials of a novel CD25‐directed antibody drug conjugate are underway.